Deep Blue Medical Advances, Inc. | $5,600,000 | (Apr 22, 2026)
NeoCognition | $40,000,000 | (Apr 22, 2026)
Ideally | $10,000,000 | (Apr 22, 2026)
Certified by Founder
Lodge
Altesa BioSciences, Inc.
start up
United States
- Atlanta, GA
- 20/02/2026
- Series B
- $75,000,000
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations -- namely viral respiratory infections -- starting with rhinovirus, the most common respiratory virus on the planet.
Our goal is to disrupt the COPD treatment paradigm by targeting the upstream cause of acute respiratory exacerbations -- not accept the status quo of managing the long term downstream consequences like chronic inflammation, hospitalizations and even death.
- Industry Biotechnology Research
- Website https://www.altesabio.com/
- LinkedIn https://www.linkedin.com/company/altesa-biosciences/
Monk | $25,000,000 | (Apr 22, 2026)
Reliable Robotics Corporation | $160,000,000 | (Apr 22, 2026)
Humble Robotics | $24,000,000 | (Apr 22, 2026)
Sinai.ai | $1,450,000 | (Apr 22, 2026)
Qualitate | $7,000,000 | (Apr 22, 2026)
Syenta | $26,000,000 | (Apr 22, 2026)
urfuture | $2,299,785 | (Apr 21, 2026)
Ultralight | $9,300,000 | (Apr 21, 2026)